Key result
Whole exome screening in CTEPH identifies 6 variants linked to acute PE, none to PAH.
Why the study?
It remained unknown whether chronic thromboembolic pulmonary hypertension, acute pulmonary embolism, and pulmonary arterial hypertension share genetic backgrounds.
Does whole exome screening identify shared genetic variants between CTEPH, APE, and PAH in Japanese patients?
Observational (n=51)
Does whole exome screening identify shared genetic variants between CTEPH, APE, and PAH in Japanese patients?
This study provides the first evidence that CTEPH patients possess genetic variants associated with acute pulmonary embolism, which differ based on their history of APE.
Hypothesis-generating for APE-specific variants in CTEPH; leaves open generalizability and clinical utility pending larger studies.
Background Although chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism (APE) share some clinical manifestations, a limited proportion of patients with CTEPH have a history of APE. Moreover, in histopathologic studies, it has been revealed that pulmonary vasculature lesions similar to pulmonary arterial hypertension existed in patients with CTEPH. Thus, it remains unknown whether these 3 disorders also share genetic backgrounds. Methods and Results Whole exome screening was performed with DNA isolated from 51 unrelated patients with CTEPH of Japanese ancestry. The frequency of genetic variants associated with pulmonary arterial hypertension or APE in patients with CTEPH was compared with those in the integrative Japanese Genome Variation Database 3.5KJPN. Whole exome screening analysis showed 17 049 nonsynonymous variants in patients with CTEPH. Although we found 6 nonsynonymous variants that are associated with APE in patients with CTEPH, there was no nonsynonymous variant associated with pulmonary arterial hypertension. Patients with CTEPH with a history of APE had nonsynonymous variants of F5 , which encodes factor V. In contrast, patients with CTEPH without a history of APE had a nonsynonymous variant of THBD , which encodes thrombomodulin. Moreover, thrombin‐activatable fibrinolysis inhibitor, which is one of the pathogenic proteins in CTEPH, was significantly more activated in those who had the variants of THBD compared with those without it. Conclusions These results provide the first evidence that patients with CTEPH have some variants associated with APE, regardless of the presence or absence of a history of APE. Furthermore, the variants might be different between patients with CTEPH with and without a history of APE.
No takes yet. Share an insight, caveat, or question.
Yaoita et al. (2020) conducted an observational in Chronic Thromboembolic Pulmonary Hypertension (n=51). Whole exome screening vs. Integrative Japanese Genome Variation Database 3.5KJPN was evaluated on Frequency of genetic variants associated with pulmonary arterial hypertension or acute pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: